Want to see AGEN full AI Analyst Report?
AGEN Stock Chart & Stats
$5.98
$0.07(1.17%)
At close: 4:00 PM EDT
$5.98
$0.07(1.17%)
Day’s Range― - ―
52-Week Range$2.71 - $8.85
Previous CloseN/A
Volume97.68K
Average Volume (3M)7.37M
Market Cap
$364.22M
Enterprise Value$391.15
Total Cash (Recent Filing)$18.74M
Total Debt (Recent Filing)$40.71M
Price to Earnings (P/E)3.0
Beta1.98
Next Earnings
Nov 10, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.72
Shares Outstanding45,020,410
10 Day Avg. Volume20,362,350
30 Day Avg. Volume7,369,170
Financial Highlights & Ratios
PEG Ratio9.24
Price to Book (P/B)-0.34
Price to Sales (P/S)0.82
P/FCF Ratio-0.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$19.50Price Target Upside226.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.89
Revenue Forecast (FY)$136.80M
Bulls Say, Bears Say
Bulls Say
Revenue And Profit TurnaroundThe sharp improvement in revenue and reported profitability strengthens internal funding capacity and indicates meaningful monetization of collaborations or assets. If partly sustained, this could improve strategic flexibility, although the earnings mix remains important.
Strategic Financing And Pipeline FocusThe financing extends the expected operating runway and concentrates resources on BOT+BAL in high-risk MSS colon cancer. A focused Phase 3 program can improve execution discipline and create a clearer path toward potential future product revenue.
Substantial Debt ReductionThe large reduction in debt lowers absolute repayment obligations and may reduce financial pressure relative to prior periods. This improves capital-structure flexibility, even though negative equity and ongoing cash consumption still limit the benefit.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means the business is not yet self-funding its research and development activities. Continued cash consumption can force additional financing, constrain trial execution, or increase dilution over the next several quarters.
Negative Shareholder EquityNegative equity reflects accumulated losses and leaves the company with a thin capital base. It reduces financial resilience, can complicate refinancing, and increases dependence on creditors or equity investors while clinical programs remain capital intensive.
Dilutive And Expensive FinancingUsing equity to meet debt obligations can dilute existing holders, while a 13% interest rate raises the recurring cost of capital. This financing dependence signals limited balance-sheet strength and may absorb resources that could otherwise support development.
Agenus News
AGEN FAQ
What was Agenus Inc.’s price range in the past 12 months?
Agenus Inc. lowest stock price was $2.71 and its highest was $8.85 in the past 12 months.
What is Agenus Inc.’s market cap?
Agenus Inc.’s market cap is $364.22M.
When is Agenus Inc.’s upcoming earnings report date?
Agenus Inc.’s upcoming earnings report date is Nov 10, 2026 which is in 79 days.
How were Agenus Inc.’s earnings last quarter?
Agenus Inc. released its earnings results on Aug 06, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of $0.045 by -$0.055.
Is Agenus Inc. overvalued?
According to Wall Street analysts Agenus Inc.’s price is currently Undervalued.
Does Agenus Inc. pay dividends?
Agenus Inc. does not currently pay dividends.
What is Agenus Inc.’s EPS estimate?
Agenus Inc.’s EPS estimate is -0.01.
How many shares outstanding does Agenus Inc. have?
Agenus Inc. has 45,020,410 shares outstanding.
What happened to Agenus Inc.’s price movement after its last earnings report?
Agenus Inc. reported an EPS of -$0.01 in its last earnings report, missing expectations of $0.045. Following the earnings report the stock price went down -3.728%.
Which hedge fund is a major shareholder of Agenus Inc.?
Currently, no hedge funds are holding shares in AGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agenus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.50 (226.09% Upside)
$19.50 (226.09% Upside)
Blogger Sentiment
Bullish
AGEN Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 18.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.76%
Trailing 12-Months
Company Description
Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
AGEN Stock 12 Month Forecast
Average Price Target
$19.50
▲(226.09% Upside)
Technical Analysis
Inovio Pharmaceuticals
―
Oncolytics Biotech
―
―
TuHURA Biosciences
―
Spero Therapeutics
―
Instil Bio
―
Ownership Overview
1.78% Insiders
9.33% Mutual Funds
4.57% Other Institutional Investors
76.34% Public Companies and
Individual Investors